Business Description
Thiogenesis Therapeutics Corp
NAICS : 325410
SIC : 3741
ISIN : CA88410L1022
Description
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.22 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -166.8 | |||||
3-Year EPS without NRI Growth Rate | -164.5 | |||||
3-Year FCF Growth Rate | -295.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.55 | |||||
9-Day RSI | 52.82 | |||||
14-Day RSI | 51.22 | |||||
3-1 Month Momentum % | -3.14 | |||||
6-1 Month Momentum % | -28.01 | |||||
12-1 Month Momentum % | 26150 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.82 | |||||
Quick Ratio | 0.82 | |||||
Cash Ratio | 0.72 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -679.52 | |||||
ROA % | -300.05 | |||||
ROCE % | -674.84 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.87 | |||||
EV-to-EBIT | -4.26 | |||||
EV-to-Forward-EBIT | -2.62 | |||||
EV-to-EBITDA | -4.26 | |||||
EV-to-Forward-EBITDA | -2.62 | |||||
EV-to-FCF | -4.96 | |||||
Earnings Yield (Greenblatt) % | -23.47 | |||||
FCF Yield % | -19.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:TTIPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Thiogenesis Therapeutics Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.102 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 36364.85 | ||
| 14-Day RSI | 51.22 | ||
| 14-Day ATR ($) | 0.004321 | ||
| 20-Day SMA ($) | 0.4185 | ||
| 12-1 Month Momentum % | 26150 | ||
| 52-Week Range ($) | 0.0016 - 0.5834 | ||
| Shares Outstanding (Mil) | 51.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Thiogenesis Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Thiogenesis Therapeutics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Thiogenesis Therapeutics Corp Frequently Asked Questions
What is Thiogenesis Therapeutics Corp(TTIPF)'s stock price today?
The current price of TTIPF is $0.42. The 52 week high of TTIPF is $0.58 and 52 week low is $0.00.
When is next earnings date of Thiogenesis Therapeutics Corp(TTIPF)?
The next earnings date of Thiogenesis Therapeutics Corp(TTIPF) is .
Does Thiogenesis Therapeutics Corp(TTIPF) pay dividends? If so, how much?
Thiogenesis Therapeutics Corp(TTIPF) does not pay dividend.
Guru Commentaries on OTCPK:TTIPF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Thiogenesis Therapeutics Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers